Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Nuvalent, Inc.NASDAQ: NUVL

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$96.25M, compared with -$84.43M a year earlier. Trailing-twelve-month EBITDA was -$334.38M.

Context

  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 11 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -151.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$96.25M-489.5% QoQ
Last fiscal yearDec 2025
-$10.49M-151.5% YoY
LTMMar 2026
-$334.38M-11.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.0%+100.0%+114.0 pp
1 year-151.5%+100.0%+251.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(10.49M) USD
Year-over-year change
-151.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.3% is the 5th highest of 9, against a peer median of -33.2%.
NUVL Competitors
EBITDA for NUVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$990.56M USD+284.7%-43.7%21.0%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026-$173.24M USD-2.5%—61.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-$176.13M USD+22.9%—22.7%
ABVXAbivax S.A.FY2025-€300.7M EUR-84.8%——
NUVLNuvalent, Inc.LTM Mar 2026-$334.38M USD-11.3%——
CRSPCRISPR Therapeutics AGLTM Sep 2026-$482.67M USD-3.6%—1917.5%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$603.58M USD-466.2%—133.9%
CYTKCytokinetics, IncorporatedLTM Jun 2026-$821.8M USD-62.8%—1158.1%
PCVXVaxcyte, Inc.LTM Jun 2026-$1.05B USD-116.2%——
Peer median (excluding NUVL) —-33.2%-43.7%97.8%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.56M63.73M113.24M217.77M306.97M
Selling, General & Admin10.26M22.38M36.25M62.59M107.34M
Operating Expenses45.82M86.11M149.49M280.37M414.31M
Depreciation & Amortization215K00280.37M414.31M
EBITDA(46.12M)(81.85M)(126.22M)20.38M(10.49M)
EBITDA Margin—————
Operating Income(45.82M)(86.11M)(149.49M)(280.37M)(414.31M)
Operating Margin—————
Interest Income0023.27M38.32M44.74M
Interest Expense0023.27M00
Other Income / Expenses(521K)4.25M23.27M20.38M(10.49M)
Income Before Tax(46.34M)(81.85M)(126.22M)(259.99M)(424.79M)
Pre-Tax Margin—————
Income Tax Expense000764K585K
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Net Margin—————
EPS (Basic)(2.13)(1.65)(2.17)(3.93)(5.85)
EPS (Diluted)(2.13)(1.65)(2.17)(3.93)(5.85)
Weighted Avg Shares21.78M49.67M58.22M66.41M72.69M
Weighted Avg Shares (Diluted)21.78M49.67M58.22M66.41M72.69M

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.